{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:55:35Z","timestamp":1791233735160,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T00:00:00Z","timestamp":1469491200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s00223-016-0177-8","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T03:27:03Z","timestamp":1469503623000},"page":"165-173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Efficacy of Osteoporosis Therapies in Diabetic Patients"],"prefix":"10.1007","volume":"100","author":[{"given":"Ann V.","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,26]]},"reference":[{"key":"177_CR1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","volume":"18","author":"P Vestergaard","year":"2007","unstructured":"Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes\u2014a meta-analysis. Osteoporos Int 18:427\u2013444","journal-title":"Osteoporos Int"},{"key":"177_CR2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/aje\/kwm106","volume":"166","author":"M Janghorbani","year":"2007","unstructured":"Janghorbani M, Van Dam RM, Willett WC, Hu FB (2007) Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166:495\u2013505","journal-title":"Am J Epidemiol"},{"key":"177_CR3","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2337\/dc15-0783","volume":"38","author":"DR Weber","year":"2015","unstructured":"Weber DR, Haynes K, Leonard MB, Willi SM, Denburg MR (2015) Type 1 diabetes is associated with an increased risk of fracture across the life span: a population-based cohort study using The Health Improvement Network (THIN). Diabetes Care 38:1913\u20131920","journal-title":"Diabetes Care"},{"key":"177_CR4","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2337\/diab.44.7.775","volume":"44","author":"JC Krakauer","year":"1995","unstructured":"Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM (1995) Bone loss and bone turnover in diabetes. Diabetes 44:775\u2013782","journal-title":"Diabetes"},{"issue":"9","key":"177_CR5","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1210\/jc.2012-1546","volume":"97","author":"JS Manavalan","year":"2012","unstructured":"Manavalan JS, Cremers S, Dempster DW, Zhou H, Dworakowski E, Kode A, Kousteni S, Rubin MR (2012) Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab 97(9):3240\u20133250","journal-title":"J Clin Endocrinol Metab"},{"key":"177_CR6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00223-010-9450-4","volume":"88","author":"P Vestergaard","year":"2011","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L (2011) Are antiresorptive drugs effective against fractures in patients with diabetes? Calcif Tissue Int 88:209\u2013214","journal-title":"Calcif Tissue Int"},{"key":"177_CR7","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1001\/jama.2011.715","volume":"305","author":"AV Schwartz","year":"2011","unstructured":"Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer ES, Ensrud KE, Donaldson MG, Cauley JA, Harris TB, Koster A, Womack CR, Palermo L, Black DM, Study of Osteoporotic Fractures Research G, Osteoporotic Fractures in Men Research G, Health A, Body Composition Research G (2011) Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305:2184\u20132192","journal-title":"JAMA"},{"key":"177_CR8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jbmr.556","volume":"27","author":"LM Giangregorio","year":"2012","unstructured":"Giangregorio LM, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2012) FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 27:301\u2013308","journal-title":"J Bone Miner Res"},{"key":"177_CR9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jbmr.2106","volume":"29","author":"JN Farr","year":"2014","unstructured":"Farr JN, Drake MT, Amin S, Melton LJ, McCready LK, Khosla S (2014) In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 29:787\u2013795","journal-title":"J Bone Miner Res"},{"key":"177_CR10","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1007\/s00198-014-2822-2","volume":"25","author":"WD Leslie","year":"2014","unstructured":"Leslie WD, Morin SN, Lix LM, Majumdar SR (2014) Does diabetes modify the effect of FRAX risk factors for predicting major osteoporotic and hip fracture? Osteoporos Int 25:2817\u20132824","journal-title":"Osteoporos Int"},{"key":"177_CR11","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","volume":"60","author":"KG Saag","year":"2009","unstructured":"Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346\u20133355","journal-title":"Arthritis Rheum"},{"key":"177_CR12","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/jcp.24929","volume":"230","author":"LM Coe","year":"2015","unstructured":"Coe LM, Tekalur SA, Shu Y, Baumann MJ, McCabe LR (2015) Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation. J Cell Physiol 230:1944\u20131953","journal-title":"J Cell Physiol"},{"key":"177_CR13","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/jcb.21573","volume":"102","author":"LR McCabe","year":"2007","unstructured":"McCabe LR (2007) Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem 102:1343\u20131357","journal-title":"J Cell Biochem"},{"key":"177_CR14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/jcp.22357","volume":"226","author":"LM Coe","year":"2011","unstructured":"Coe LM, Irwin R, Lippner D, McCabe LR (2011) The bone marrow microenvironment contributes to type I diabetes induced osteoblast death. J Cell Physiol 226:477\u2013483","journal-title":"J Cell Physiol"},{"key":"177_CR15","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/diacare.27.7.1547","volume":"27","author":"TH Keegan","year":"2004","unstructured":"Keegan TH, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL (2004) Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care 27:1547\u20131553","journal-title":"Diabetes Care"},{"key":"177_CR16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fendo.2013.00062","volume":"4","author":"AV Schwartz","year":"2013","unstructured":"Schwartz AV, Ewing SK, Porzig AM, McCulloch CE, Resnick HE, Hillier TA, Ensrud KE, Black DM, Nevitt MC, Cummings SR, Sellmeyer DE (2013) Diabetes and change in bone mineral density at the hip, calcaneus, spine, and radius in older women. Front Endocrinol (Lausanne) 4:62","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"177_CR17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00223-015-0071-9","volume":"98","author":"D Inoue","year":"2015","unstructured":"Inoue D, Muraoka R, Okazaki R, Nishizawa Y, Sugimoto T (2015) Efficacy and safety of risedronate in osteoporosis subjects with comorbid diabetes, hypertension, and\/or dyslipidemia: a post hoc analysis of phase III trials conducted in Japan. Calcif Tissue Int 98(2):114\u2013122","journal-title":"Calcif Tissue Int"},{"key":"177_CR18","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/BF02877778","volume":"24","author":"S Dagdelen","year":"2007","unstructured":"Dagdelen S, Sener D, Bayraktar M (2007) Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. Adv Ther 24:1314\u20131320","journal-title":"Adv Ther"},{"key":"177_CR19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.diabres.2011.03.033","volume":"93","author":"J Iwamoto","year":"2011","unstructured":"Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H (2011) Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Diabetes Res Clin Pract 93:166\u2013173","journal-title":"Diabetes Res Clin Pract"},{"key":"177_CR20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.08.010","volume":"68","author":"ZN Zhu","year":"2014","unstructured":"Zhu ZN, Jiang YF, Ding T (2014) Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 68:115\u2013123","journal-title":"Bone"},{"key":"177_CR21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00198-012-2184-6","volume":"24","author":"B Abrahamsen","year":"2013","unstructured":"Abrahamsen B, Rubin KH, Eiken PA, Eastell R (2013) Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study. Osteoporos Int 24:321\u2013328","journal-title":"Osteoporos Int"},{"key":"177_CR22","unstructured":"Schwartz A, Bauer D, Cummings S, Grey A, McClung M, Napoli N, Reid I, Schafer A, Wallace R, Black D (2015) Bisphosphonates reduce fracture risk in postmenopausal women with diabetes: results from FIT and HORIZON-PFT trials. J Bone Miner Res 30(Suppl 1). http:\/\/www.asbmr.org\/education\/AbstractDetail?aid=2c9d5b7e-f1fc-474f-942b-9238dbcdab63 . Accessed 2 Apr 2016"},{"key":"177_CR23","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ, Grp FITR (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures\u2014results from the fracture intervention trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"177_CR24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"177_CR25","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637\u2013645","journal-title":"JAMA"},{"key":"177_CR26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00774-012-0379-8","volume":"31","author":"H Mori","year":"2013","unstructured":"Mori H, Okada Y, Kishikawa H, Inokuchi N, Sugimoto H, Tanaka Y (2013) Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes. J Bone Miner Metab 31:89\u201395","journal-title":"J Bone Miner Metab"},{"key":"177_CR27","doi-asserted-by":"crossref","first-page":"464","DOI":"10.5812\/ijem.3794","volume":"10","author":"O Saito","year":"2012","unstructured":"Saito O, Saito T, Asakura S, Akimoto T, Inoue M, Ando Y, Muto S, Kusano E (2012) Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes. Int J Endocrinol Metab 10:464\u2013469","journal-title":"Int J Endocrinol Metab"},{"key":"177_CR28","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1359\/jbmr.040211","volume":"19","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Black DM, Balogh A, Poor G, Sarkar S, Zhou C, Pavo I (2004) Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res 19:764\u2013772","journal-title":"J Bone Miner Res"},{"key":"177_CR29","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1359\/jbmr.070904","volume":"23","author":"KE Ensrud","year":"2008","unstructured":"Ensrud KE, Stock JL, Barrett-Connor E, Grady D, Mosca L, Khaw KT, Zhao Q, Agnusdei D, Cauley JA (2008) Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J Bone Miner Res 23:112\u2013120","journal-title":"J Bone Miner Res"},{"key":"177_CR30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125\u2013137","journal-title":"N Engl J Med"},{"key":"177_CR31","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1359\/jbmr.060404","volume":"21","author":"E Seeman","year":"2006","unstructured":"Seeman E, Vellas B, Benhamou C, Aquino JP, Semler J, Kaufman JM, Hoszowski K, Varela AR, Fiore C, Brixen K, Reginster JY, Boonen S (2006) Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 21:1113\u20131120","journal-title":"J Bone Miner Res"},{"key":"177_CR32","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s00774-013-0494-1","volume":"31","author":"JJ Stepan","year":"2013","unstructured":"Stepan JJ (2013) Strontium ranelate: in search for the mechanism of action. J Bone Miner Metab 31:606\u2013612","journal-title":"J Bone Miner Metab"},{"key":"177_CR33","unstructured":"Health EMASM (2013) Recommendation to restrict the use of Protelos\/Osseor (strontium ranelate). EMA\/258269\/2013"},{"key":"177_CR34","unstructured":"Health EMASM (2014) Protelos\/Osseor to remain available but with further restrictions. EMA\/235924\/2014"},{"key":"177_CR35","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00198-013-2469-4","volume":"25","author":"B Abrahamsen","year":"2014","unstructured":"Abrahamsen B, Grove EL, Vestergaard P (2014) Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporos Int 25:757\u2013762","journal-title":"Osteoporos Int"},{"key":"177_CR36","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00198-013-2582-4","volume":"25","author":"C Cooper","year":"2014","unstructured":"Cooper C, Fox KM, Borer JS (2014) Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD. Osteoporos Int 25:737\u2013745","journal-title":"Osteoporos Int"},{"key":"177_CR37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF02489947","volume":"15","author":"T Sato","year":"1997","unstructured":"Sato T, Sato K (1997) The effects of intermittent administration of human parathyroid hormone (1\u201334) on streptozotocin-induced diabetic rats. J Bone Miner Metab 15:145\u2013152","journal-title":"J Bone Miner Metab"},{"key":"177_CR38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/PL00005838","volume":"66","author":"T Tsuchida","year":"2000","unstructured":"Tsuchida T, Sato K, Miyakoshi N, Abe T, Kudo T, Tamura Y, Kasukawa Y, Suzuki K (2000) Histomorphometric evaluation of the recovering effect of human parathyroid hormone (1\u201334) on bone structure and turnover in streptozotocin-induced diabetic rats. Calcif Tissue Int 66:229\u2013233","journal-title":"Calcif Tissue Int"},{"key":"177_CR39","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/jcp.22844","volume":"227","author":"KJ Motyl","year":"2012","unstructured":"Motyl KJ, McCauley LK, McCabe LR (2012) Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survival. J Cell Physiol 227:1326\u20131334","journal-title":"J Cell Physiol"},{"key":"177_CR40","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/jbmr.2210","volume":"29","author":"RJ Fajardo","year":"2014","unstructured":"Fajardo RJ, Karim L, Calley VI, Bouxsein ML (2014) A review of rodent models of type 2 diabetic skeletal fragility. J Bone Miner Res 29:1025\u20131040","journal-title":"J Bone Miner Res"},{"key":"177_CR41","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1210\/en.2013-1960","volume":"155","author":"C Hamann","year":"2014","unstructured":"Hamann C, Picke AK, Campbell GM, Balyura M, Rauner M, Bernhardt R, Huber G, Morlock MM, Gunther KP, Bornstein SR, Gluer CC, Ludwig B, Hofbauer LC (2014) Effects of parathyroid hormone on bone mass, bone strength, and bone regeneration in male rats with type 2 diabetes mellitus. Endocrinology 155:1197\u20131206","journal-title":"Endocrinology"},{"issue":"5","key":"177_CR42","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370(5):412\u2013420","journal-title":"N Engl J Med"},{"key":"177_CR43","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","volume":"30","author":"RR Recker","year":"2015","unstructured":"Recker RR, Benson CT, Matsumoto T, Bolognese MA, Robins DA, Alam J, Chiang AY, Hu L, Krege JH, Sowa H, Mitlak BH, Myers SL (2015) A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 30:216\u2013224","journal-title":"J Bone Miner Res"},{"key":"177_CR44","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.1803","volume":"28","author":"C Hamann","year":"2013","unstructured":"Hamann C, Rauner M, Hohna Y, Bernhardt R, Mettelsiefen J, Goettsch C, Gunther KP, Stolina M, Han CY, Asuncion FJ, Ominsky MS, Hofbauer LC (2013) Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res 28:627\u2013638","journal-title":"J Bone Miner Res"},{"key":"177_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O\u2019Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the american society for bone and mineral research. J Bone Miner Res 29:1\u201323","journal-title":"J Bone Miner Res"},{"key":"177_CR46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O\u2019Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sandor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, International Task Force on Osteonecrosis of the J (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3\u201323","journal-title":"J Bone Miner Res"},{"key":"177_CR47","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","volume":"374","author":"DM Black","year":"2016","unstructured":"Black DM, Rosen CJ (2016) Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med 374:254\u2013262","journal-title":"N Engl J Med"},{"key":"177_CR48","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.bone.2010.12.033","volume":"48","author":"A Giusti","year":"2011","unstructured":"Giusti A, Hamdy NA, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE (2011) Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 48:966\u2013971","journal-title":"Bone"},{"key":"177_CR49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bone.2012.02.632","volume":"51","author":"JC Lo","year":"2012","unstructured":"Lo JC, Huang SY, Lee GA, Khandelwal S, Provus J, Ettinger B, Gonzalez JR, Hui RL, Grimsrud CD (2012) Clinical correlates of atypical femoral fracture. Bone 51:181\u2013184","journal-title":"Bone"},{"key":"177_CR50","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cell.2010.06.003","volume":"142","author":"M Ferron","year":"2010","unstructured":"Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G (2010) Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142:296\u2013308","journal-title":"Cell"},{"key":"177_CR51","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/jbmr.1865","volume":"28","author":"AV Schwartz","year":"2013","unstructured":"Schwartz AV, Schafer AL, Grey A, Vittinghoff E, Palermo L, Lui LY, Wallace RB, Cummings SR, Black DM, Bauer DC, Reid IR (2013) Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials. J Bone Miner Res 28:1348\u20131354","journal-title":"J Bone Miner Res"},{"key":"177_CR52","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00223-011-9515-z","volume":"89","author":"P Vestergaard","year":"2011","unstructured":"Vestergaard P (2011) Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate. Calcif Tissue Int 89:265\u2013270","journal-title":"Calcif Tissue Int"},{"key":"177_CR53","doi-asserted-by":"crossref","first-page":"e0123279","DOI":"10.1371\/journal.pone.0123279","volume":"10","author":"DC Chan","year":"2015","unstructured":"Chan DC, Yang RS, Ho CH, Tsai YS, Wang JJ, Tsai KT (2015) The use of alendronate is associated with a decreased incidence of type 2 diabetes mellitus\u2013a population-based cohort study in Taiwan. PLoS One 10:e0123279","journal-title":"PLoS One"},{"key":"177_CR54","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nm.3084","volume":"19","author":"S Kiechl","year":"2013","unstructured":"Kiechl S, Wittmann J, Giaccari A, Knoflach M, Willeit P, Bozec A, Moschen AR, Muscogiuri G, Sorice GP, Kireva T, Summerer M, Wirtz S, Luther J, Mielenz D, Billmeier U, Egger G, Mayr A, Oberhollenzer F, Kronenberg F, Orthofer M, Penninger JM, Meigs JB, Bonora E, Tilg H, Willeit J, Schett G (2013) Blockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med 19:358\u2013363","journal-title":"Nat Med"},{"key":"177_CR55","unstructured":"Napoli N, Vittinghoff E, Pannacciulli N, Crittenden D, Yun J, Wang A, Wagman R, Schwartz A (2014) Effect of denosumab on fasting glucose concentrations in postmenopausal women with osteoporosis: results from subjects with diabetes or prediabetes from the FREEDOM trial. J Bone Miner Res 29(Suppl 1). http:\/\/www.asbmr.org\/education\/AbstractDetail?aid=4a6b0c87-cdcb-45f7-bf5c-ab3836239296 . Accessed 2 Apr 2016"},{"key":"177_CR56","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0149-2918(03)80114-5","volume":"25","author":"E Barrett-Connor","year":"2003","unstructured":"Barrett-Connor E, Ensrud KE, Harper K, Mason TM, Sashegyi A, Krueger KA, Anderson PW (2003) Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther 25:919\u2013930","journal-title":"Clin Ther"},{"key":"177_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-138-1-200301070-00005","volume":"138","author":"AM Kanaya","year":"2003","unstructured":"Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, Cauley JA, Barrett-Connor E, Heart and Estrogen, progestin Replacement S (2003) Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen\/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 138:1\u20139","journal-title":"Ann Intern Med"},{"key":"177_CR58","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00125-004-1448-x","volume":"47","author":"KL Margolis","year":"2004","unstructured":"Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, Bassford T, Burke G, Torrens J, Howard BV, Women\u2019s Health Initiative I (2004) Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women\u2019s Health Initiative Hormone Trial. Diabetologia 47:1175\u20131187","journal-title":"Diabetologia"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-016-0177-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-016-0177-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-016-0177-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-016-0177-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T14:02:05Z","timestamp":1568210525000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-016-0177-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,26]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["177"],"URL":"https:\/\/doi.org\/10.1007\/s00223-016-0177-8","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,26]]}}}